Helping donors and funders carry out vaccine development programs

VFI supports the vision of a healthier world with tried and trusted expertise and network.

VFI is striving to open up access to relevant knowledge for the development of affordable and efficient adjuvanted vaccines. VFI’s funding by the Bill & Melinda Gates Foundation and the European Commission underline VFI’s not-for-profit engagement for the benefit of developing countries.

Current funders

Bill & Melinda Gates Foundation (BMGF)

VAGH

VAGH (VFI Adjuvants for Global Health) aims at developing a broad portfolio of adjuvants for use in Global Health vaccines.

VAGH

Visit website

GH-VAP

The Global Health Vaccine Accelerator Platforms links BMGF-funded activities with best-in-class research services in order to accelerate vaccine development.

GH-VAP

VFI provides adjuvants, formulation studies, as well as immunogenicity testing and quality control. Thus far, VFI has run over 30 projects for vaccine developers on numerous vaccine candidates, including against Repiratory Syncytial Virus, COVID-19, Inactivated Polio, HIV, Tuberculosis, Malaria, Influenza and other diseases.

Visit website

Reference:
Marcandalli, J. et al. Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus. Cell 176, 1420-1431.e17 (2019).

Coalition for Epidemic Preparedness Innovations (CEPI)

CEPI

Development of an Effective Subunit Vaccine Against SARS-CoV-2 Variants as a Platform Technology“ is a project led by VIDO (Vaccine and Infectious Disease Organization) at the University of Saskatchewan, Canada.

CEPI

The project aims to develop a second generation of VIDO’s vaccine candidate COVAC-2, a COVID-19 protein subunit vaccine formulated with Sepivac SWE™, an adjuvant co-developed by VFI and Seppic. The new vaccine candidate will be developed to broaden the immune response to SARS-CoV-2 Variants of Concern, and VFI will provide its expertise on formulation to develop a one-vial formulation vaccine.

Visit website

European Commission (EC)

TRANSVAC

TRANSVAC aims at developing a sustainable vaccine infrastructure for Europe.

TRANSVAC

VFI coordinates TRANSVAC activities and provides training as well as adjuvant and formulation services.

Visit website

Reference:
Geels, M. J. et al. TRANSVAC research infrastructure – Results and lessons learned from the European network of vaccine research and development. Vaccine 33, 5481–5487 (2015)

ENOVA

ENOVA, the European Network Of Vaccine Adjuvants, was initiated by the VFI team which has gathered a group of European experts and stakeholders working on vaccine adjuvants.

ENOVA

ENOVA is funded by COST (European Cooperation in Science & Technology) and aims to establish a platform to discuss, share and synergize available knowledge on adjuvants and vaccine formulation, and ultimately to coordinate their translation into successful, safe and innovative vaccines.

Visit website

Reference:
Schijns, V. et al. Modulation of immune responses using adjuvants to facilitate therapeutic vaccination. Immunol Rev 296, 169–190 (2020) and Lemoine, C. et al. Technological Approaches for Improving Vaccination Compliance and Coverage. Vaccines 8, 304 (2020)